In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

Research indicates that its unique design may allow it to act as an ... as compared to single-receptor agonists. The peptide structure of Tirzepatide includes modifications that are believed ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

which may have been influenced by the study’s 72-week primary phase design. In conclusion, the trial shows that tirzepatide therapy could lead to sustained weight loss and significantly reduce ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said Maria ...

Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of tirzepatide ...